Year: 2023

MINNEAPOLIS, Nov. 07, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2023.Revenue of $2.4 million for the third quarter 2023, increased 16% over the prior quarter and increased 17% over the prior-year period. Therapy utilization, or the number of circuits per placed console, increased 26% over the prior year, reflecting continued increases in the number of patients treated with the Aquadex® therapy. By customer category, third quarter 2023 revenue in Heart Failure increased 27% over the same period last year, Critical Care and Pediatrics increased 16% and 9%, respectively. Despite continuing hospital capital budget constraints, our installed console...

Strategic Initiatives Continue to Drive Higher Returns and Generate Strong Cash Flow COLUMBUS, Ohio, Nov. 07, 2023 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reports financial and operating results for the fiscal periods ended September 30, 2023. Third Quarter 2023 HighlightsNet sales of $86.7 million, compared to $101.6 million in the prior year; and product sales of $80.9 million, down 12.4% from the prior year. Product sales increased by 19.6% on a cumulative basis over two years from 2021 levels when combining...

Third quarter net sales of $145.3 million up 11.8% year over year (10.0% adjusted for non-routine items1). Adjusted organic growth1 was 12.6% partially offset by portfolio changes of 2.6%. Gross profit of $28.2 million up 22.2% year over year (up 12.1% adjusted for non-routine items1); gross margins of 19.4% up 160 basis points (“bps”) year over year, (up 40 bps for the quarter and 250 bps for the year-to-date period adjusted for non-routine items1). Third quarter net income of $0.5 million was favorable $2.6 million year over year; third quarter adjusted EBITDA1 of $10.6 million up 14.2% year over year. Strong cash flow generation reduced net debt1 by $16.9 million during the quarter to $68.7 million at quarter end; Gross Leverage Ratio1 improved to 2.0x at quarter end compared to 2.5x last quarter and 3.3x at last year’s...

Data from dose escalation study for CRB-701, a Nectin-4 ADC to treat solid tumors, on track for release in early 2024 along with start of U.S./EU Study IND Submission for CRB-601, an αvβ8 Monoclonal Antibody to treat solid tumors, on track for Q4 2023 Pre-clinical data for CRB-913, a peripherally restricted CB1 inverse agonist, published in Obesity and presented at Obesity WeekNORWOOD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the third quarter of 2023. “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief...

Financial Overview – Third QuarterRevenues of $139 Million, Down 4% From a Year Ago Adjusted Operating Income Margin of 8.5%, GAAP Operating Loss Margin of (19.2)% Adjusted EPS of $0.12; GAAP Diluted EPS of $(0.27)Financial Overview – Nine MonthsRevenues of $436 Million, Down 3% From a Year Ago Adjusted Operating Income Margin of 8.9%, GAAP Operating Loss Margin of (16.3)% Adjusted EPS of $0.37; GAAP Diluted EPS of $(0.84)Talent Investment and Strategic ActionsContinue to Add Senior Bankers to Expand Client Coverage Footprint and Accelerate Growth Year-To-Date Added Six New Partners and Seven New Managing Directors Additional Partner Expected to Join Firm in the Fourth Quarter and a Further Partner in 2024Capital ManagementStrong Balance Sheet with $197 Million of Cash and Short-Term Investments and No Debt Year-to-Date...

Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADC Preparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADC Capital resources expected to support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ETCAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2023. “Our team has made considerable progress on multiple fronts in recent months as we seek to demonstrate the clinical...

– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Bavdegalutamide mCRPC data presented at ESMO showed median rPFS of 11.1 months in patients with AR 878/875 tumor mutations, demonstrating the potential for a PROTAC® AR degrader in prostate cancer – – New interim data from second generation PROTAC AR degrader support the Company’s decision to prioritize the initiation of a Phase 3 trial with ARV-766 in mCRPC instead of the previously planned Phase 3 trial for bavdegalutamide – NEW HAVEN, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial...

Company generates strong quarterly results, while continuing to invest in growth opportunities Company to Host Conference Call Today at 9 a.m. ET MIAMI, Nov. 07, 2023 (GLOBE NEWSWIRE) — International Money Express, Inc. (NASDAQ: IMXI) (“Intermex” or the “Company”), one of the nation’s leading omnichannel money transfer services to Latin America, today reported strong operating results for the third quarter of 2023. Bob Lisy, Chairman, President, and CEO of Intermex, stated, “We are proud to beat market consensus for Revenue and deliver another strong quarter of growth. In line with our expectations, Net Income was impacted by non-core items this year and last, however Adjusted EBITDA grew at 14%, also ahead of our projections. The profitability and cash generation of our underlying operations have allowed us to invest to accelerate...

Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end Company anticipates the initiation of multiple Phase 3 programs by year-end EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results and highlighted recent portfolio activities expected to drive long-term shareholder value. “Our existing royalty portfolio continues to mature, driven by increasing cash receipts of VABYSMO® and IXINITY® and the advancement of several assets, most notably the New Drug Application (NDA) filing of tovorafenib by Day One Biopharmaceuticals,” stated Owen Hughes,...